Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458726 | 0.85 | LRRK2 (1.00) | LRRK2JAK2ALKINSRIGF1R | |
| SCHEMBL19654261 | 0.81 | ULK1 (0.70) | LRRK2ULK1ALKINSRIGF1R | |
| SCHEMBL7453776 | 0.80 | LRRK2 (0.77) | LRRK2ALK | |
| SCHEMBL7448853 | 0.80 | LRRK2 (0.70) | LRRK2ALK | |
| SCHEMBL17547513 | 0.77 | ULK1 (1.00) | LRRK2ULK1JAK2ALK | |
| SCHEMBL29574731 | 0.77 | ULK1 (1.00) | LRRK2ULK1JAK2ALK | |
| SCHEMBL27380982 | 0.74 | LRRK2 (0.72) | LRRK2ULK1JAK2 | |
| SCHEMBL28507855 | 0.73 | LRRK2 (0.58) | LRRK2ULK1ALKINSRIGF1R | |
| SCHEMBL24716030 | 0.73 | LRRK2 (0.56) | LRRK2ALK | |
| SCHEMBL24716041 | 0.73 | LRRK2 (0.56) | LRRK2ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801493-B | It is used to treat the 2- Phenyl aminopyrimidine derivants of Parkinson's disease as kinases LRRK2 conditioning agents | 健泰科生物技术公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-105837519-A | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | 霍夫曼-拉罗奇有限公司 | 2016-08-10 | — | — | CN | disclosed |